Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma | MicrobiomeTrials← Back to trialsNCT06762769
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-06-02Est. Completion: 2032-11-01
Enrollment target: 63 participants Locations- St James University Hospital, Leeds, Leeds, United Kingdom
- Churchill Hospital, Oxford, Oxford, United Kingdom
- Aberdeen Royal Infirmary, Aberdeen, United Kingdom
- University of Birmingham Hospital, Birmingham, United Kingdom
- Bristol NHS Foundation Trust, Bristol, United Kingdom
- Cardiff and Vale University Health Board, Cardiff, United Kingdom
- University Hospitals of Derby and Burton, Derby, United Kingdom
- Barts Health Trust, London, United Kingdom
- University College London Hospital, London, United Kingdom
- King's College Hospital NHS Foundation Trust, London, United Kingdom
- St Georges Hospital, London, United Kingdom
- Nottingham City Hospital, Nottingham, United Kingdom
- George Eliot Hospital, Nuneaton, United Kingdom
- Glan Clwyd Hospital, Wales, United Kingdom
Other microbiome trials you might be interested in
Smoldering Multiple Myeloma
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smold…
Birmingham, United StatesEst. completion Feb 27, 2029
High Risk Smoldering Multiple Myeloma (HR-SMM)
This study is researching an experimental drug called linvoseltamab (also called "study drug") compared to another drug …
Phoenix, United StatesEst. completion Jul 27, 2033
Contact